Effects	0	7	O
of	8	10	O
doxycycline	11	22	B-Drug_or_compound
on	23	25	O
in	26	28	O
vitro	29	34	O
growth	35	41	O
,	41	42	O
migration	43	52	O
,	52	53	O
and	54	57	O
gelatinase	58	68	O
activity	69	77	O
of	78	80	O
breast	81	87	B-Cell
carcinoma	88	97	I-Cell
cells	98	103	I-Cell
.	103	104	O

Metastatic	106	116	O
disease	117	124	O
is	125	127	O
one	128	131	O
of	132	134	O
the	135	138	O
major	139	144	O
causes	145	151	O
of	152	154	O
death	155	160	O
from	161	165	O
cancer	166	172	B-Pathological_formation
in	173	175	O
human	176	181	B-Organism
beings	182	188	O
.	188	189	O

Several	190	197	O
enzyme	198	204	O
systems	205	212	O
have	213	217	O
been	218	222	O
implicated	223	233	O
in	234	236	O
the	237	240	O
metastatic	241	251	O
process	252	259	O
,	259	260	O
but	261	264	O
the	265	268	O
metalloproteinases	269	287	B-Gene_or_gene_product
(	288	289	O
MPs	289	292	B-Gene_or_gene_product
)	292	293	O
appear	294	300	O
to	301	303	O
be	304	306	O
the	307	310	O
major	311	316	O
group	317	322	O
involved	323	331	O
in	332	334	O
most	335	339	O
instances	340	349	O
of	350	352	O
neoplastic	353	363	O
invasion	364	372	O
.	372	373	O

Increased	374	383	O
MP	384	386	B-Gene_or_gene_product
activity	387	395	O
has	396	399	O
been	400	404	O
correlated	405	415	O
with	416	420	O
the	421	424	O
metastatic	425	435	O
potential	436	445	O
of	446	448	O
many	449	453	O
cancers	454	461	B-Pathological_formation
,	461	462	O
including	463	472	O
breast	473	479	B-Pathological_formation
cancer	480	486	I-Pathological_formation
.	486	487	O

MPs	488	491	B-Gene_or_gene_product
also	492	496	O
play	497	501	O
a	502	503	O
role	504	508	O
in	509	511	O
tumor	512	517	B-Pathological_formation
angiogenesis	518	530	O
.	530	531	O

Tetracyclines	532	545	B-Drug_or_compound
are	546	549	O
antimicrobial	550	563	O
agents	564	570	O
that	571	575	O
can	576	579	O
suppress	580	588	O
MP	589	591	B-Gene_or_gene_product
activity	592	600	O
in	601	603	O
a	604	605	O
variety	606	613	O
of	614	616	O
tissues	617	624	B-Tissue
,	624	625	O
including	626	635	O
gingiva	636	643	B-Multi-tissue_structure
,	643	644	O
bone	645	649	B-Tissue
,	649	650	O
and	651	654	O
cartilage	655	664	B-Tissue
.	664	665	O

Several	666	673	O
reports	674	681	O
have	682	686	O
indicated	687	696	O
that	697	701	O
tetracyclines	702	715	B-Drug_or_compound
can	716	719	O
suppress	720	728	O
tumor	729	734	B-Pathological_formation
MPs	735	738	B-Gene_or_gene_product
as	739	741	O
well	742	746	O
.	746	747	O

A	748	749	O
synthetic	750	759	O
tetracycline	760	772	B-Drug_or_compound
,	772	773	O
doxycycline	774	785	B-Drug_or_compound
,	785	786	O
inhibits	787	795	O
migration	796	805	O
of	806	808	O
human	809	814	B-Organism
MDA	815	818	B-Cell
-	818	819	I-Cell
MB	819	821	I-Cell
-	821	822	I-Cell
435	822	825	I-Cell
breast	826	832	I-Cell
adenocarcinoma	833	847	I-Cell
cells	848	853	I-Cell
through	854	861	O
a	862	863	O
reconstituted	864	877	O
basement	878	886	B-Cellular_component
membrane	887	895	I-Cellular_component
(	896	897	O
Matrigel	897	905	O
)	905	906	O
,	906	907	O
an	908	910	O
assay	911	916	O
used	917	921	O
as	922	924	O
an	925	927	O
in	928	930	O
vitro	931	936	O
surrogate	937	946	O
for	947	950	O
the	951	954	O
in	955	957	O
vivo	958	962	O
process	963	970	O
of	971	973	O
tumor	974	979	B-Pathological_formation
invasion	980	988	O
through	989	996	O
basement	997	1005	B-Cellular_component
membranes	1006	1015	I-Cellular_component
.	1015	1016	O

Additionally	1017	1029	O
,	1029	1030	O
doxycycline	1031	1042	B-Drug_or_compound
diminishes	1043	1053	O
the	1054	1057	O
proliferation	1058	1071	O
of	1072	1074	O
this	1075	1079	O
breast	1080	1086	B-Cell
cancer	1087	1093	I-Cell
cell	1094	1098	I-Cell
line	1099	1103	I-Cell
and	1104	1107	O
also	1108	1112	O
decreases	1113	1122	O
its	1123	1126	O
gelatinolytic	1127	1140	O
activity	1141	1149	O
,	1149	1150	O
as	1151	1153	O
determined	1154	1164	O
by	1165	1167	O
gel	1168	1171	O
zymography	1172	1182	O
.	1182	1183	O

